- Home
- GNFT vs ZURA Comparison
GNFT vs ZURA Comparison
Compare GNFT & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- ZURA
- Stock Information
- Founded
- GNFT 1999
- ZURA 2022
- Country
- GNFT France
- ZURA United States
- Employees
- GNFT N/A
- ZURA N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNFT Health Care
- ZURA Health Care
- Exchange
- GNFT Nasdaq
- ZURA Nasdaq
- Market Cap
- GNFT 186.3M
- ZURA 69.9M
- IPO Year
- GNFT 2019
- ZURA N/A
- Fundamental
- Price
- GNFT $3.75
- ZURA $1.31
- Analyst Decision
- GNFT Strong Buy
- ZURA Buy
- Analyst Count
- GNFT 1
- ZURA 7
- Target Price
- GNFT $13.00
- ZURA $14.33
- AVG Volume (30 Days)
- GNFT 3.8K
- ZURA 708.2K
- Earning Date
- GNFT 04-24-2025
- ZURA 08-08-2025
- Dividend Yield
- GNFT N/A
- ZURA N/A
- EPS Growth
- GNFT N/A
- ZURA N/A
- EPS
- GNFT 0.03
- ZURA N/A
- Revenue
- GNFT $73,187,701.00
- ZURA N/A
- Revenue This Year
- GNFT $15.98
- ZURA N/A
- Revenue Next Year
- GNFT N/A
- ZURA N/A
- P/E Ratio
- GNFT $120.71
- ZURA N/A
- Revenue Growth
- GNFT 105.01
- ZURA N/A
- 52 Week Low
- GNFT $2.55
- ZURA $0.97
- 52 Week High
- GNFT $6.42
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- GNFT 44.52
- ZURA 59.63
- Support Level
- GNFT $3.44
- ZURA $1.00
- Resistance Level
- GNFT $3.81
- ZURA $1.45
- Average True Range (ATR)
- GNFT 0.17
- ZURA 0.10
- MACD
- GNFT -0.00
- ZURA 0.03
- Stochastic Oscillator
- GNFT 56.65
- ZURA 68.89
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.